Tag: Oxford University

Posted on

HyunJu Kwak for Ridgewood BOE

242910590 115362630890383 7226644335073802097 n

photo of HyunJu Kwak at Brown graduation

Dear Ridgewood,
I grew up in Paramus in an immigrant family with modest means. I loved going to school, and whatever time I had left, I worked as a cashier at a local supermarket to pay my way for activities like a school trip to Paris. I knew that education was an investment towards a better future and school was a gateway to opportunities. I had a view, thanks to my parents, that if I work diligently, I can make a difference in myself and the world.

Continue reading HyunJu Kwak for Ridgewood BOE

Posted on

AstraZeneca Faces Hurdles to Regulatory Approval of COVID19 Vaccine

AstraZeneca
 the staff of the Ridgewood blog
Ridgewood NJ, previously reported on the Ridgewood blog that AstraZeneca issued a press release regarding preliminary results from the Phase 3 clinical trials of its candidate SARS-CoV-2 vaccine, developed in collaboration with Oxford University (UK). According to Johns Hopkins Center for Health Security ,the press release indicates that the vaccine demonstrated 90% efficacy when administered as an initial half-dose followed by a full dose a month later. Interestingly, however, the vaccine was 62% efficacious in participants who received 2 full doses over the same period of time, resulting in an overall efficacy of 70%. No serious adverse events were identified in the trials. In total, the Phase 3 portion of the trials included more than 11,000 participants, and the researchers identified 131 COVID-19 cases. As has been the case throughout the pandemic, the data published via press release have not yet been peer reviewed, although the researchers reportedly intend to publish the full data in the near future.

Continue reading AstraZeneca Faces Hurdles to Regulatory Approval of COVID19 Vaccine

Posted on

AstraZeneca’s COVID19 Vaccine Trial Paused Over Safety Concerns

AstraZeneca

the staff of the Ridgewood blog

Oxford UK, The Phase 3 clinical trial for AstraZeneca’s candidate SARS-CoV-2 vaccine (developed in collaboration with Oxford University) has been paused following the identification of a serious adverse event in one of the participants. Neither AstraZeneca nor Oxford University have yet disclosed details of the adverse event, which reportedly occurred in the UK; however, The New York Times reports that the patient developed transverse myelitis. It has not yet been determined whether the condition was associated with the vaccine. An earlier clinical trial for the AstraZeneca vaccine was also paused following the diagnosis of transverse myelitis in a participant, but the trial resumed after a safety review determined that the condition was not related to the vaccine.

Continue reading AstraZeneca’s COVID19 Vaccine Trial Paused Over Safety Concerns

Posted on

Two COVID19 Vaccines Show Promising Results

outbreak coronavirus world 1024x683px 1

the staff of the Ridgewood blog

Ridgewood NJ, two studies were published in The Lancet, describing results of clinical trials for candidate vaccines from China and the UK. The candidate from Chinese pharmaceutical manufacturer CanSino is a single-dose vaccine that utilizes a recombinant adenovirus vector. The associated trial was a randomized, double-blind, placebo-controlled Phase 2 trial that involved 508 healthy human volunteers in Wuhan, China. Two dosages were tested, and both demonstrated high seroconversion after 4 weeks (96% and 97%, respectively) and significant neutralizing antibody response. Severe adverse reactions were reported in 9% of those receiving the higher dose and 1% of those receiving the lower dose, a statistically significant difference. Based on these results, the researchers intend to conduct a Phase 3 trial for the lower vaccine dose in the near future.

Continue reading Two COVID19 Vaccines Show Promising Results